Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial.
Effets du renversement du bloc neuromusculaire à l’aide de sugammadex vs de la néostigmine sur l’évolution respiratoire postopératoire après une chirurgie abdominale majeure: une étude randomisée contrôlée.
Abdomen
/ surgery
Aged
Female
Humans
Male
Middle Aged
Neostigmine
/ administration & dosage
Neuromuscular Blockade
/ methods
Postoperative Complications
/ epidemiology
Pulmonary Atelectasis
/ epidemiology
Respiratory Function Tests
Single-Blind Method
Spirometry
Sugammadex
/ administration & dosage
Vital Capacity
Journal
Canadian journal of anaesthesia = Journal canadien d'anesthesie
ISSN: 1496-8975
Titre abrégé: Can J Anaesth
Pays: United States
ID NLM: 8701709
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
11
09
2018
accepted:
22
04
2019
revised:
11
04
2019
pubmed:
6
6
2019
medline:
23
10
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
Postoperative pulmonary complications may be better reduced by reversal of neuromuscular block with sugammadex than by reversal with neostigmine because the incidence of residual block after sugammadex application is lower and diaphragm function is less impaired than after neostigmine administration. The aim of the study was to compare the effect of reversal of neuromuscular block with sugammadex or neostigmine on lung function after major abdominal surgery. One hundred and thirty adults scheduled for major abdominal surgery under combined general and epidural anesthesia were randomly allocated to receive 40 µg of neostigmine or 4 mg·kg One hundred twenty-six patients were included in the main analysis. In the neostigmine group (n = 64), mean (95% confidence interval [95% CI]) reduction in FVC after one hour was 0.5 (0.4 to 0.6) L. In the sugammadex group (n = 62), the mean (95% CI) reduction in FVC during the first hour was 0.5 (95% CI, 0.3 to 0.6) L. Thirty-nine percent of patients in the neostigmine group and 29% in the sugammadex group had visible atelectasis. Median [interquartile range (IQR)] atelectasis area was 9.7 [4.7-13.1] cm We found no differences in pulmonary function in patients reversed with sugammadex or neostigmine in a high-risk population. EudraCT 2014-005156-26; registered 27 May, 2015.
Identifiants
pubmed: 31165457
doi: 10.1007/s12630-019-01419-3
pii: 10.1007/s12630-019-01419-3
doi:
Substances chimiques
Sugammadex
361LPM2T56
Neostigmine
3982TWQ96G
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1328-1337Subventions
Organisme : Merck
ID : ID# 51875